 SALT LAKE CITY, Dec. 10, 2021 GLOBE NEWSWIRE -- Clene Inc. NASDAQ: CLNN along with its subsidiaries Clene and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative disease, presented data from the RESCUE-ALS Phase 2 study of CNM-Au8, a catalytically active gold nanocrystal suspension, for the treatment of amyotrophic lateral sclerosis ALS in a late-breaking oral presentation at the 32nd International Symposium on ALSMND, Dec. 10, 2021 at 1:05 pm ET. The presentation can be viewed after the presentation on Clenes website at: 